These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38005968)

  • 1. Comparative Immune Response after Vaccination with SOBERANA
    Pérez-Nicado R; Massa C; Rodríguez-Noda LM; Müller A; Puga-Gómez R; Ricardo-Delgado Y; Paredes-Moreno B; Rodríguez-González M; García-Ferrer M; Palmero-Álvarez I; Garcés-Hechavarría A; Rivera DG; Valdés-Balbín Y; Vérez-Bencomo V; García-Rivera D; Seliger B
    Vaccines (Basel); 2023 Oct; 11(11):. PubMed ID: 38005968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
    Toledo-Romaní ME; Valenzuela-Silva C; Montero-Díaz M; Iñiguez-Rojas L; Rodríguez-González M; Martínez-Cabrera M; Puga-Gómez R; German-Almeida A; Fernández-Castillo S; Climent-Ruiz Y; Santana-Mederos D; López-González L; Morales-Suárez I; Doroud D; Valdés-Balbín Y; García-Rivera D; Van der Stuyft P; Vérez-Bencomo V
    Lancet Reg Health Am; 2024 Jun; 34():100750. PubMed ID: 38699214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Eugenia-Toledo-Romaní M; Verdecia-Sánchez L; Rodríguez-González M; Rodríguez-Noda L; Valenzuela-Silva C; Paredes-Moreno B; Sánchez-Ramírez B; Pérez-Nicado R; González-Mugica R; Hernández-García T; Bergado-Baez G; Pi-Estopiñán F; Cruz-Sui O; Fraga-Quintero A; García-Montero M; Palenzuela-Díaz A; Baró-Román G; Mendoza-Hernández I; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; Ramírez Gonzalez U; García-Vega Y; Pérez-Massón B; Guang-Wu-Chen ; Boggiano-Ayo T; Ojito-Magaz E; Rivera DG; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V; ; Gómez-Maceo Y; Reyes-Matienzo R; Manuel Coviella-Artime J; Morffi-Cinta I; Martínez-Pérez M; Castillo-Quintana I; Garcés-Hechavarría A; Valera-Fernández R; Martínez-Bedoya D; Garrido-Arteaga R; Cardoso-SanJorge F; Quintero Moreno L; Ontivero-Pino I; Teresa Pérez-Guevara M; Morales-García M; Noa-Romero E; Orosa-Vázquez I; Díaz-Hernández M; Rojas G; Tundidor Y; García-López E; Muñoz-Morejon Y; Galano-Frutos E; Rodríguez-Alvarez J; Arteaga A; Medina Nápoles M; Espi Ávila J; Fontanies Fernández M
    Vaccine; 2022 Jul; 40(31):4220-4230. PubMed ID: 35691871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
    Toledo-Romaní ME; García-Carmenate M; Valenzuela-Silva C; Baldoquín-Rodríguez W; Martínez-Pérez M; Rodríguez-González M; Paredes-Moreno B; Mendoza-Hernández I; González-Mujica Romero R; Samón-Tabio O; Velazco-Villares P; Bacallao-Castillo JP; Licea-Martín E; Rodríguez-Ortega M; Herrera-Marrero N; Caballero-González E; Egües-Torres L; Duartes-González R; García-Blanco S; Pérez-Cabrera S; Huete-Ferreira S; Idalmis-Cisnero K; Fonte-Galindo O; Meliá-Pérez D; Rojas-Remedios I; Doroud D; Gouya MM; Biglari A; Fernández-Castillo S; Climent-Ruiz Y; Valdes-Balbín Y; García-Rivera D; Van der Stuyft P; Verez-Bencomo V;
    Lancet Reg Health Am; 2023 Feb; 18():100423. PubMed ID: 36618081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
    Toledo-Romani ME; García-Carmenate M; Verdecia-Sánchez L; Pérez-Rodríguez S; Rodriguez-González M; Valenzuela-Silva C; Paredes-Moreno B; Sanchez-Ramirez B; González-Mugica R; Hernández-Garcia T; Orosa-Vázquez I; Díaz-Hernández M; Pérez-Guevara MT; Enriquez-Puertas J; Noa-Romero E; Palenzuela-Diaz A; Baro-Roman G; Mendoza-Hernández I; Muñoz Y; Gómez-Maceo Y; Santos-Vega BL; Fernandez-Castillo S; Climent-Ruiz Y; Rodríguez-Noda L; Santana-Mederos D; García-Vega Y; Chen GW; Doroud D; Biglari A; Boggiano-Ayo T; Valdés-Balbín Y; Rivera DG; García-Rivera D; Vérez-Bencomo V;
    Med; 2022 Nov; 3(11):760-773.e5. PubMed ID: 35998623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein.
    Hassan PM; Ali T; Saber E; Asghar A; Delaram D; Mostafa SV; Maryam S; Maryam K; Talieh S; Ali KM; Mohammad P; Fereidoon K; Anahita B; Yury VB; Dagmar GR; Vicente VB; Alireza B; Kazem B
    Vaccine; 2022 May; 40(20):2856-2868. PubMed ID: 35393148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV2 wild type and mutant specific humoral and T cell immunity is superior after vaccination than after natural infection.
    Richardson JR; Götz R; Mayr V; Lohse MJ; Holthoff HP; Ungerer M
    PLoS One; 2022; 17(4):e0266701. PubMed ID: 35468147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
    Puga-Gómez R; Ricardo-Delgado Y; Rojas-Iriarte C; Céspedes-Henriquez L; Piedra-Bello M; Vega-Mendoza D; Pérez NP; Paredes-Moreno B; Rodríguez-González M; Valenzuela-Silva C; Sánchez-Ramírez B; Rodríguez-Noda L; Pérez-Nicado R; González-Mugica R; Hernández-García T; Fundora-Barrios T; Echevarría MD; Enriquez-Puertas JM; Infante-Hernández Y; Palenzuela-Díaz A; Gato-Orozco E; Chappi-Estévez Y; Francisco-Pérez JC; Suarez-Martinez M; Castillo-Quintana IC; Fernandez-Castillo S; Climent-Ruiz Y; Santana-Mederos D; García-Vega Y; Toledo-Romani ME; Doroud D; Biglari A; Valdés-Balbín Y; García-Rivera D; Vérez-Bencomo V;
    Int J Infect Dis; 2023 Jan; 126():164-173. PubMed ID: 36403819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination.
    Liang B; Xiang T; Wang H; Li Z; Quan X; Feng X; Li S; Lu S; Fan L; Xu L; Wang T; Wang X; Zhu B; Wang J; Yang D; Liu J; Zheng X
    Front Immunol; 2022; 13():966098. PubMed ID: 35979361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
    Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
    Front Immunol; 2021; 12():793191. PubMed ID: 34975897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
    Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
    Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity.
    Ghaemi A; Roshani Asl P; Zargaran H; Ahmadi D; Hashimi AA; Abdolalipour E; Bathaeian S; Miri SM
    Front Immunol; 2022; 13():974364. PubMed ID: 36159845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Serological Analysis of the Humoral Immune Responses of Anti-RBD IgG, Anti-S1 IgG, and Anti-S2 IgG Levels Correlated to Anti-N IgG Positivity and Negativity in Sicilian Healthcare Workers (HCWs) with Third Doses of the mRNA-Based SARS-CoV-2 Vaccine: A Retrospective Cohort Study.
    Serra N; Andriolo M; Butera I; Mazzola G; Sergi CM; Fasciana TMA; Giammanco A; Gagliano MC; Cascio A; Di Carlo P
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Robust Vaccine-Induced as Well as Hybrid B- and T-Cell Immunity across SARS-CoV-2 Vaccine Platforms in People with HIV.
    Verburgh ML; van Pul L; Grobben M; Boyd A; Wit FWNM; van Nuenen AC; van Dort KA; Tejjani K; van Rijswijk J; Bakker M; van der Hoek L; Schim van der Loeff MF; van der Valk M; van Gils MJ; Kootstra NA; Reiss P
    Microbiol Spectr; 2023 Jun; 11(3):e0115523. PubMed ID: 37166335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
    Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
    J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.